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Abstract
Background: Despite growing evidence for manualized psychodynamic treatments, there is a lack of studies on their
transfer to routine practice. This is the first study to examine the effects of an additional training in manualized Short
Term Psychodynamic Psychotherapy (STPP) on the outcome in routine psychotherapy for social anxiety disorder (SAD).
The study is an extension to a large RCT comparing STPP to Cognitive-Behavioral Therapy of SAD.
Methods: The manualized treatment was designed for a time limited approach with 25 individual sessions of STPP
over 6 months. Private practitioners were randomized to training in manualized STPP (mSTPP) vs. treatment as usual
without a specific training (tauSTPP). A total of 109 patients were enrolled (105 started treatment; 75 completed at least
20 treatment sessions). Assessments were conducted pre-treatment, after 8 and 15 weeks, after 25 treatment sessions,
at the end of treatment, 6 and 12 months after termination of treatment. Remission as primary outcome was defined
by the Liebowitz-Social-Anxiety-Scale (LSAS) score ≤30. Secondary outcomes were response (at least 31% reduction in
LSAS), treatment duration and number of sessions, changes in social anxiety (LSAS, SPAI), depression (BDI), clinical
global impression (CGI), and quality of life (EQ-5D).
Results: Remission rates of mSTPP (9%) resp. tauSTPP (16%) and also response rates of 33% resp. 28% were comparable
between the two treatment approaches as well as treatment duration and number of sessions. Most of the within-group
differences (baseline to 25 sessions) indicated moderate to large improvements in both treatments; within-group differences
from baseline to 12 months follow-up (LSAS, SPAI, BDI, CGI) were large ranging from d=−0.605 to d =−2.937. Benefits of
mSTPP were limited to single outcomes.
Conclusions: Findings are discussed with regard to implementation and dissemination of empirically validated treatments
in psychodynamic training and practice. SAD patients with a high comorbidity of personality disorders and a long treatment
history may need longer treatments.
Trial registration: German Clinical Trials Register (DRKS) DRKS00000570, registered 03. March 2011.
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Background
Social anxiety disorder (SAD) is a highly prevalent dis-
order with an average 12 month prevalence rate between
2% in the German [1–3] and 7.4% in the US population
[4]. Women develop a SAD more frequently than men;
mean onset is between 10 and 16.6 years [5, 6]. The
course of SAD is usually chronic and full remission is
seldom [7]. Affected persons tend to suffer from comor-
bid disorders such as depression, personality disorders,
other anxiety disorders or substance abuse [5]. SAD is
often misinterpreted as shyness, unrecognized and
undertreated [5, 7].
About half of all psychotherapies in German clinical
practice are psychodynamic psychotherapies [8], how-
ever, the quality and effectiveness of psychodynamic psy-
chotherapy for SAD is unknown. Many psychodynamic
practitioners are biased against structured short-term
treatment approaches and disorder specific manualized
treatments have rarely been used in psychodynamic
training and practice.
In a recent trial of the Social Phobia Network (Sopho-
Net funded by the German Federal Ministry of Educa-
tion and Research, BMBF) remission rates of cognitive
therapy, psychodynamic therapy and waiting list were
36, 26 and 8%, respectively. Response rates were 60, 52,
and 15% [9]. Cognitive therapy and psychodynamic ther-
apy were equally effective in treating SAD in the long
run [10], but there were statistically significant short-
term differences in favor of cognitive therapy at the end
of treatment in some measures (remission, self-reported
social anxiety, interpersonal problems), but not in other
measures (response, depression). In addition, the differ-
ences were small and below the a priori defined thresh-
old of clinical significance [9].
Dissemination and implementation of efficacious,
evidence-based treatments into practice has become a
growing issue in mental health care [11]. As psychodynamic
manualized treatments have only recently been developed
for anxiety disorders, there has been a paucity of research
on dissemination and implementation of empirically vali-
dated manuals (cf. for an example for panic disorder [12]).
It is unknown whether new treatment approaches will im-
prove the effects of routine psychodynamic psychotherapy.
However, meta-analytical findings indicate the superiority
of strictly manualized STPP [13] compared to mostly non--
manualized STPP for the reduction of general psychiatric
symptoms [14, 15]. Therefore it is important to investigate
how the manualized psychodynamic treatment evaluated in
the first funding period of the Social Phobia Network [10]
can be transferred from controlled trials into routine
clinical care and whether the health care system benefits
from such developments.
The central objective of this trial was to analyze the ef-
fects of the implementation of manualized Short Term
Psychodynamic Psychotherapy (STPP) into routine out-
patient care and to test its effects in comparison to com-
mon psychodynamic treatment practiced.
We hypothesized that treatment effects reached by pri-
vate practitioners trained with the manualized procedure
of STPP will be superior to therapists who apply their
usual psychodynamic treatment and that the implemen-
tation of manualized STPP will lead to an average reduc-
tion of treatment duration.
Methods
Study design
The time period from the start of patient recruitment to
completion of follow-up was from April 26, 2011, to
June 9, 2015.
In a randomized controlled trial in a naturalistic set-
ting, psychodynamic psychotherapists were randomized
either to a training in manualized STPP for social
anxiety disorder [16, 17], or to no additional training.
Practitioners in the training group (referred to as
manualized STPP, mSTPP) received two separate blocks
of training, each block with a mean duration of about
five clock hours.
The final study protocol and the final version of the
written informed consent form were approved by the
Ethics Committee of the Statutory Physician Board of
Rhineland Palatinate (Germany), which is responsible for
the Principal Investigator (Ref. No. 037.249.10 [7258])
and the Data Safety Monitoring Committee (DSMC).
The study was monitored by the Interdisciplinary Center
for Clinical Trials (IZKS) of the University Medical
Center of the Johannes Gutenberg University Mainz.
The study was registered at the German Clinical Trials
Register (DRKS) DRKS00000570. The study adheres to
the CONSORT guidelines.




The study was carried out at three trial sites. The
participating sites were the Clinic for Psychosomatic Medi-
cine and Psychotherapy of the University Medical Center,
Johannes Gutenberg University, Mainz, the Department of
Psychosomatics and Psychotherapy, University of Giessen
and the Department of Psychosomatic Medicine and
Psychotherapy, Medical Faculty Carl Gustav Carus, Tech-
nical University of Dresden.
Therapists
All officially listed (chambers of psychotherapists and
medical doctors) psychodynamic psychotherapists in the
regions of the trial sites were asked to participate as study
therapists. All participating therapists had undergone and
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completed their training in psychodynamic psychotherapy,
which usually takes 5 years to complete. Due to the
intended naturalistic character of our study we defined
broad inclusion criteria for the participating therapists.
Therapists could be of any age and gender. Therapists
having participated in the first funding period of the
Sopho-Net, and therefore trained and experienced in
STPP for social anxiety disorder, were excluded.
A total of 49 therapists participated as study therapists.
Twenty-eight of them were female. Therapists reported
having practiced as psychotherapists since an average of
14.7 (SD = 10.4) years. Only 12 therapists reported
having experience with manualized treatments. There
was no significant difference between the therapists
treating mSTPP vs. tauSTPP regarding their experience
as psychotherapists (M = 14.6, SD 0.6 vs. M = 14.8, SD
11.4 years, p = .939) and their number of treated patients
during the study (M = 2.3, SD = 1.4 vs. M = 2.1, SD = 1.1,
p = .588).
All participating therapists were randomly assigned ei-
ther to a training group which underwent a brief train-
ing of the short-term STPP manual for SAD (mSTPP) as
developed for the multi-center study or to a control group
which continued their routine treatments (non-manualized
standard psychodynamic treatment, tauSTPP).
Randomization was stratified taking into account the
three trial sites. Randomization of therapists was per-
formed centrally by IZKS Mainz by FAX with a 1:1
randomization ratio using permuted blocks before their
training started. Patients were not randomized and did
not know whether their therapist was recently trained in
STPP for social anxiety disorder or not. As a compensa-
tion for their contribution (patient recruitment, ratings),
therapists received 200€ per each documented patient.
Participants
In contrast to other RCTs it was initially planned that pa-
tients were recruited by private practitioners and not by the
trial sites. For this purpose participating therapists reported
patients potentially fulfilling inclusion criteria and willing to
participate in the study procedure to the trial site where
diagnostics were performed. Due to a delay in recruitment,
we decided to additionally recruit through the outpatient
clinics of the participating trial sites. In this case, patients
first underwent the diagnostic procedure. In contrast to
other RCTs participants, they were not randomized to ther-
apists, but they selected their preferred therapist from a list
of participating therapists without knowing whether the
therapist had been trained in mSTPP or not.
Patients’ inclusion and exclusion criteria are listed in
Table 1.
A total of 109 patients were enrolled in the study. One
hundred and five patients started treatment and 75 com-
pleted at least 20 sessions of the scheduled 25 treatment
sessions. A total of 32 patients completed the entire
study procedure including a 12 months follow-up. Drop-
out rates until 25-sessions assessment were slightly but
not significantly higher in the mSTPP group (mSTPP
22/58 vs tauSTPP 12/51, p = 0.147, Fisher’s exact test).
Fig. 1 shows the patient flow.
There were no significant differences between the two
groups regarding gender ratio, age, marital status and
education.
Patients treated by therapists trained in mSTPP had
more often undergone a psychotherapeutic inpatient
treatment in the past and their social anxiety disorder
was judged more severe. Table 2 gives an overview of
the patient characteristics.
Training
All therapists randomized to mSTPP studied the manual
on mSTPP [16, 17]. They were additionally trained in
this approach in two workshops of about five clock
hours each by AH, FL and PJ. mSTPP therapists were
offered site level supervision about every 12 weeks by
AH, FL and PJ; tauSTPP therapists were invited to case
discussions with the same frequency.
Interventions
The manualized intervention was based on Luborsky’s
Supportive Expressive Therapy (SET) and has been de-
scribed elsewhere [15–17]. The treatment was custom-
ized to 25 individual sessions of STPP over 6 months
(short-term therapy, as reimbursed by the German
health insurance).
Patients in the control condition received standard
psychodynamic treatment.
Table 1 Inclusion and exclusion criteria
Inclusion criteria •Diagnosis of SAD (Structured Clinical Interview for
DSM, SCID-I, [18]) and Liebowitz Social Anxiety Scale
>30 (>60 for generalized subtype) [LSAS, 19, 20]
•age: 18 to 70 years
•SAD must be primary diagnosis (most severe disorder
according to ADIS-IV)
•SAD patients with comorbid disorders will be
included, provided that SAD is the primary diagnosis,
thus ensuring a clinically representative sample as
well as analyses of subgroups (e.g. type of SAD,
patients with comorbid depressive disorder)
•Informed consent
Exclusion criteria •psychotic disorder
•prominent risk of self-harm
•acute substance related disorders
•personality disorders except for cluster C: avoidant,





•psychopharmacological treatment (stable medical
treatments; e.g. SSRI without dose adaptation
are permitted)
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In both conditions therapists were encouraged to limit
treatments to 25 sessions (á 50 min), but due to the nat-
uralistic character of the study their treatments were not
limited to 25 sessions. In addition to the aforementioned
25 or more treatment sessions, up to five preparatory
sessions (á 50 min) were conducted which are required
within the German health care system to cover diagnos-
tic and administrative issues.
Assessment
Assessments were conducted before treatment started,
after 8 and 15 weeks, after 25 treatment sessions, at the
end of treatment, 6 and 12 months after termination of
treatment. If treatment exceeded 25 sessions an add-
itional post-treatment assessment was performed imme-
diately after termination.
Patients were assessed by independent and trained
SCID/LSAS interviewers, who were blind to the treatment
condition, i.e. patients did not know, whether their thera-
pists were trained in mSTPP or not. Patients were
instructed to not report specific contents of their treat-
ment sessions in order to not reveal the treatment arm to
the interviewers. Allocation checks were not performed.
A detailed overview of the assessment in the study can
be found elsewhere [15].
Outcomes
The primary outcome measure was the Liebowitz Social
Anxiety Scale observer rating (LSAS-OR [19], German
version: [20]). Following recommendations by Liebowitz
et al. [21], remission was defined by a Liebowitz-Social-
Anxiety-Scale score ≤30 [21, 22]. The primary endpoint
was the assessment after 25 sessions.
Secondary outcome measures included response to
treatment (see below), treatment duration and number
of sessions, the LSAS self-rating (LSAS-SR), another
scale for the assessment of social anxiety (Social Phobia
and Anxiety Inventory, SPAI, [23], German version: [24])
and scales for clinical global impression (CGI, [25]),
depression (Beck Depression Inventory, BDI, [26]; Ger-
man version: [27]), quality of life and social functioning
(EQ-5D, [28]).
Response was defined by a 31% reduction (or more) in
the Liebowitz-Social-Anxiety-Scale which is comparable
to Clinical Global Impression Improvement scale score
≤2 usually used to define response [29].
Fig. 1 Patient flow. 1) ITT sample 2) mITT sample 3) Finished at least 20 treatment sessions 4) Completer sample
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All instruments were applied in both groups of this
trial. Using established cut-off scores for LSAS, the per-
centages of patients defined as remitted was assessed
and statistically compared between the mSTPP and
tauSTPP.
Treatment adherence and treatment differentiation
Due to the naturalistic character of the study we
refrained from systematic video- or audiotaping of the
treatment sessions; sessions were occasionally video-
taped, when therapist and patient both agreed with the
recording. In order to determine the therapists’ treat-
ment adherence we devised self-rating scales for patients
and therapists based on J. Barber’s Penn Adherence
Competence Scale (PACS-SE, [30]). An observer rating
of the PACS-SE identifying adherence to supportive,
expressive and social anxiety specific interventions has
already been applied in the first funding phase of Sopho-
Net [9]. Additionally, patients were asked to report ac-
tivities between treatment sessions. These activities were
related to treatment (e.g. I thought about the end of
treatment and its relevance for me) or specific interven-
tions of the treatment manual (e.g. I checked my anxiety
formula critically). We expected participants treated
with mSTPP to score higher on the total scale and on
those items referring to interventions from the manual.
The scales were administered after 25 treatment
sessions.
Therapist’s allegiance
Prior to treatment, therapists completed a modified ver-
sion of the Reaction to Treatment Questionnaire devel-
oped by Holt and Heimberg assessing treatment
allegiance for every treated patient [31]. Items are scaled
from one (not at all confident or logical) to ten (very
logical or confident).
Statistical analyses
At a conservative drop-out rate of 25% (taking into ac-
count slightly elevated drop-outs in a practice study), a
total of N = 105 patients were required to be allocated to
the trial. Thus, we initially planned to include N = 35
patients in each center. Details on sample size calcula-
tion can be found elsewhere [15].
Remission rates were compared between treatments
by logistic regression with covariates for treatment, sex,
and experience of the therapist. A cluster randomized
trial would require an additional term for therapist in
the analysis model. However, this was skipped because
of the low number of patients per center. The primary
analysis was focused on all patients who started the ther-
apy. Missing values were replaced by the last observation
carried forward (LOCF) method. Post-hoc the LSAS data
Table 2 Patient characteristics (ITT sample, N = 109)
Parameter mSTPP (N = 58) tauSTPP (N = 51) Total (N = 109) p-value
Female (%) 29 (50) 24 (47) 53 (49) .848 +
Age (SD) 33,1 (9.8) 30,7 (8.7) 32 (9.3) .168 *
Marital status Single 36 (77) 39 (81) 75 (79) .746 +
Married 7 (15) 7 (15) 14 (15)
Divorced 4 (9) 2 (4) 6 (6)
Years at school (SD) 11.9 (1.5) 11.7 (1.7) 11.8 (1.6) .715 *
Professional education University degree 12 (20) 14 (27) 26 (23) .908 +
Severity of primary diagnosis (0–8) Mean (SD) 6.1 (1.0) 5.6 (1.2) 5.9 (1.1) .038 *
Number of mental diagnoses Mean (SD) 1.7 (1.0) 1.4 (1.1) 1.5 (1.0) .071 *
Personality disorders N (%) 29 (51.79) 24 (47.06) 53 (49.53) .625 +
Comorbid diagnoses Non 5 (8.93) 12 (23.53) 17 (15.89) .027 +
One 21 (37.50) 16 (31.37) 37 (34.58)
two 16 (28.57) 19 (37.25) 35 (32.71)
Three and more 14 (25.00) 4 (7.84) 18 (16.82)
Treatment history
Outpatient psychotherapy N (%) 28 ( 50) 23 (45) 51 (48) .699 +
Inpatient psychotherapy N (%) 18 ( 32) 6 ( 12) 24 ( 22) .019 +
Outpatient psychiatric treatment N (%) 14 ( 25) 7 ( 14) 21 ( 20) .150 +
Inpatient psychiatric treatment N (%) 6 ( 11) 3 ( 6) 9 ( 8) .491 +
* p-values are calculated with the T-Test between treatments according to Satterthwaite
+ p-values are calculated with Fisher’s Exact test
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analysis was repeated for sensitivity by using multiple
imputation. All baseline parameters with a correlation of
more than 0.3 were used for imputation of the LSAS
values. Remission and response were calculated from the
imputed LSAS values. The imputation was repeated ten
times by using a chained equation method.
Secondary analyses
Self-report questionnaires and observer ratings (SPAI,
BDI, CGI and EQ-5D, treatment adherence) were ana-
lysed by mixed models with repeated measurements.
All analyses were interpreted on a two-sided level of
significance of 0.05.
Additional analyses
As sensitivity analyses, the analysis was repeated for the
per protocol population and a chi-square test was per-
formed. Also the LSAS (observer and self-rating) were an-
alyzed as a continuous measure by means of a mixed
model with repeated measurements (MMRM) with fixed
effects for treatment, sex and experience of the therapist,
week in study and an interaction term of week in study
and treatment. This meant especially that data from week
8 and week 15 were included. We used compound sym-
metry (pre-specified) as a covariance structure and esti-
mated treatment effects within a restricted maximum
likelihood (REML). The MMRM allows a fuller use of the
data compared to an ANCOVA. Missing values might be
predicted by other included data, therefore an MMRM is
able to deal with data missing at random (MAR).
As social anxiety was more severe, the mental comor-
bidity was higher, and pre-treatment inpatient psycho-
therapy was more frequent in the mSTPP group at
baseline, we performed post-hoc subgroup analyses for
the above mentioned variables separately by incorporat-
ing additional terms for the variable and an interaction
term into the mixed model analyses. Between-group dif-
ferences were not affected significantly by the covariate
adjustment of the analyses.
For quantification of effect sizes Cohen’s d for con-
tinuous outcomes and Cohen’s h—as a measure of dif-
ference between two probabilities or proportions—for
dichotomous outcomes within and between treatment
conditions were calculated. For the calculation of
Cohen’s h the proportion p in each group was trans-
formed by means of γ = 2 arcsin(p). Afterwards the
difference between the γ for each group was calculated.
The interpretation of the resulting effect sizes is similar
to Cohen’s d.
Results
Treatment adherence and treatment differentiation
Due to missing data we could analyze a total of 61 ad-
herence questionnaires from the patients’ perspective.
For the total scale of 17 items we found a higher agree-
ment to the items (p < .001) in mSTPP (M = 14.56, SD =
1.95) compared to M = 11.24 (SD 3.79) in tauSTPP.
As expected behaviours referring to specific interven-
tions of the treatment manual (e.g. I checked my anxiety
formula critically) were more often practiced by patients
treated with mSTPP. Table 3 gives an overview.
Data of adherence to mSTPP rated by the therapists
could be analyzed for a total of 86 patients.
Therapists treating with mSTPP did not differ in their
ratings of the frequency of supportive interventions dur-
ing the treatment (p = .415) compared to the tauSTPP
therapists (M = 5.63, SD = 0.77 vs. M = 5.50, SD = 0.75).
For the expressive subscale we also could not
observe a difference (p = .7548) between the treatment
settings (mSTPP: M = 5.28, SD = 0.97 vs. tauSTPP: M
= 5.22, SD = 0.87).
Both settings differed (p < .001) with regards to the fre-
quency of treatment techniques specific for the manua-
lized treatment of social anxiety disorders: M = 5.31, SD
= 1.01 for mSTPP vs. M = 4.50, SD = 0.87 for tauSTPP.
Therapists’ allegiance
Therapists of the mSTPP group reported an average alle-
giance score of M= 8.61 (SD= 1.11), the tauSTPP therapists
of M= 8.17 (SD= 1.38). There was no significant difference
(p= .108) in the subjective allegiance to treatment.
Primary outcome
Remission rates (mITT sample) were 9% for mSTPP and
16% for tauSTPP after 25 treatment sessions. Controlled
for sex and experience of the therapist in a logistic re-
gression model the difference between the treatment
conditions was not significant (OR = .75 [.19–2.93], p
= .681) with a small effect size of Cohen’s h = −.214. On
top of that multiple imputation revealed a non-
significant result with p = .857.
Remission rates after end of treatment were 13% for
mSTPP and 16% for tauSTPP, after 6 months 15% resp.
20%, and after 12 months 22% resp. 26%.
Secondary outcomes
Response rates (mITT sample) were 33% for mSTPP and
28% for tauSTPP. Again, controlled for sex and experi-
ence of the therapist in a logistic regression model the
difference between the treatment conditions was not
significant (OR = 1.24 [.49–3.16], p = .656; Cohen’s h =
−.109). On top of that multiple imputation revealed a
non-significant result with a notably smaller p-value of
p = .267.
Means and standard deviations for LSAS-OR, LSAS-
SR, SPAI, BDI, CGI and EQ-5D at baseline, after 25 ses-
sions and at 12-months follow-up are listed in Table 4.
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Most of the within-group differences (baseline to 25
sessions) were large for both treatment settings (mSTPP
and tauSTPP). Only LSAS-OR for tauSTPP showed a
decline with a small effect size of d = −.445 from baseline
to 25 sessions, and EQ-5D showed only a small increase
for both treatment groups.
Most of the effect sizes of the long-term within-group
differences (baseline to 12 months follow-up) were larger
than the short-term within-group differences (baseline to
25 sessions) ranging from d = −0.605 to d = −2.937.
EQ-5D showed a large improvement in mSTPP and a
large decrease in tauSTPP from baseline to follow-up.
Table 4 gives an overview.
All between-group differences after 25 treatment ses-
sions were small to medium with effect sizes ranging be-
tween −0.33 and 0.21 (see Table 4).
For the between groups differences at 12-month
follow-up we found small effects for LSAS-OR, LSAS-
SR, SPAI, CGI, and BDI (see Table 4).
Quality of life (EQ-5D) was significantly higher in
patients treated with mSTPP 12 months after treatment
(M = 77.27, SD = 15.42 vs. M = 49.14, SD = 38.47 for
tauSTPP). The effect size for this difference was large
(d = 0.90). Table 4 gives an overview.
Treatment duration
The mean duration of treatments was comparable (p
= .602): 68.13 weeks (SD 41.23) in mSTPP and
63.56 weeks (SD = 28.34) in tauSTPP. The time until 25
sessions did not differ between the two groups (p
= .373): 37.68 weeks (SD 14.70) in mSTPP and
40.58 weeks (SD = 12.90) in tauSTPP. A total of 29
(35.4%) treatments exceeded 25 sessions.
The total number of sessions until treatment ended
did not differ significantly between the treatments: 36.35
sessions (SD = 34.48) for mSTPP and 33.86 sessions (SD
= 23.52) for tauSTPP (p = .7047).
Discussion
As the first of this kind, our study compared the effects
of manualized STPP and STPP as usually being prac-
ticed by therapists in their private practice in a sample
of patients with SAD.
Allegiance to treatments was high and did not differ
significantly between the two groups.
Due to the naturalistic character of our study we did
not perform regular adherence checks to ensure
treatment integrity. However, from the patient’s perspec-
tive we could differentiate treatments by retrospective
Table 3 Adherence/treatment differentiation
mSTPP (N = 27) tauSTPP (N = 34) p-value *
N (%) N (%)
Not specific for mSTPP
1. I reflected issues from the therapy. 27 (100) 32 (94.12) .200
2. I practiced what we have discussed in the therapy. 27 (100) 30 (89.24) .065
7. I thought about demanding high standards of myself. 24 (88.89) 29 (85.29) .680
8. I thought about situations making me anxious. 27 (100) 28 (82.35) .022
11. I thought about my behavior in social situations. 27 (100) 32 (94.12) .200
12. I tried different behavior in such situations. 20 (74.07) 23 (67.65) .585
13. I thought about my therapist. 21 (77.78) 27 (79.41) .877
17. I thought about the end of treatment and its relevance for me. 20 (74.07) 21 (61.76) .309
Specific for mSTPP
3. I thought about my “anxiety formula”. 23 (85.19) 14 (42.42) .001
4. I checked my “anxiety formula” critically (e.g. will my fears really
become true?)
23 (85.19) 15 (44.12) .001
5. I thought about encouraging myself. 22 (81.48) 16 (47.06) .006
6. I practiced encouraging myself. 21 (77.78) 12 (35.29) .001
9. I went into situations making me anxious. 27 (100) 25 (75.76) .006
10. I thought about my experiences in these situations. 27 (100) 28 (82.35) .022
14. I tried not to devaluate myself. 23 (88.46) 26 (76.47) .234
15. I imagined situations observing me and others on a stage like
being among the audience.
10 (37.04) 4 (11.76) .020
16. I thought about when and why I feel ashamed. 24 (88.89) 20 (58.82) .009
Analysis Set = mITT Population (N = 105)
* p-values are calculated with Chi2 – Tests
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assessment of their activities between the therapy ses-
sions. Furthermore, therapists reported a higher adher-
ence to interventions specific for the treatment of social
anxiety in the mSTPP group.
We hypothesised that the manualized procedure of
STPP will be superior to usual psychodynamic treatment
and lead to an average reduction of treatment duration.
In our naturalistic setting remission rates after 25
treatment sessions (mSTPP 9%, tauSTPP 16%) did not
differ significantly between the two treatment groups.
Treatments were not shorter compared to tauSTPP.
Effect size differences between the two treatment
groups were small for most secondary outcomes.
However, most effect sizes were—albeit insignifican-
tly—higher in the mSTPP group from baseline to
treatment termination. Depression was lower and
quality of life was higher after a follow-up of 1 year
in the mSTPP group. Indeed, quality of life had
moderately increased in mSTPP and moderately de-
creased in tauSTPP.
These results can be seen as being disappointing.
While moderate to large effect sizes were achieved for
most outcomes in both conditions, the rates of response
and remission were low and below the findings from the
main study [9].
The transfer of new therapeutic strategies from an
RCT was neither superior regarding the main outcome
nor regarding the duration of treatment. Reasons for this
lack of differences are multifarious. Firstly, despite of
randomization of therapists, patients in the mSTPP
group were more seriously ill regarding the severity of
the social anxiety disorder and also had more comorbid
diagnoses, which was likely to adversely affect remission
rates [32, 33] and also may have caused the slightly, but
not significantly higher drop-out rate in the mSTPP
group. Secondly, compared to the study of Leichsenring
et al. [9], in this study, therapists did not treat pilot pa-
tients with the manual before starting with study treat-
ments, and frequency of supervision was much lower.
Therefore, we assume that the familiarity with the man-
ual was also lower in this study. Thirdly, we did not re-
strict treatments to 25 sessions. As usual in German
routine care, therapists were free to decide about treat-
ment duration based on their professional evaluation.
Maybe, therapists have acted less straight forwardly in
conducting their therapy, because they were free to ex-
tend the therapy.
In the previous randomized controlled trial [9] we
found higher remission rates (26%) for mSTPP after 25
treatment sessions, almost comparable to our current
Table 4 Estimated means and standard deviations of scores on social anxiety, depression and psychopathology measures at
baseline (T0b), after 25 sessions and 12-months follow-up and effect sizes of between- and within-group differences
Measures Baseline 25 Sessions Follow-up ES (within-group)
baseline – 25 sessions
ES (within-group)
baseline – follow-up
Group M (SD) M (SD) M (SD) d [95% CI] d [95% CI]
LSAS-OR mSTPP 77.77 (23.43) 51.85 (23.25 42.87 (27.06) -.946 [−1.32, −.57] −1.228 [−1.83, −.62]
tauSTPP 69.15 (24.71) 55.93 (26.98) 38.18 (23.60) -.445 [−.84, −.05] −1.231 [−1.92, −.54]
ES (between); d [95% CI] .36 [−.03, .75] -.16 [−.65, .33] .19 [−.57, .94]
LSAS-SRa mSTPP 81.28 (27.70) 54.29 (28.28) 44.57 (27.59) -.821 [−1.14, −.50] −1.035 [−1.58, −.49]
tauSTPP 76.12 (23.94) 52.08 (23.76) 44.81 (22.69) -.951 [−1.41, −.49] −1.309 [−2.05, −.56]
ES (between); d [95% CI] .20 [−.22, .62] .08 [−.47, .64] -.01 [−.78, .76]
SPAIb mSTPP 5.36 (0.85) 4.38 (1.26) 3.92 (1.12) −1.023 [−1.35, −0.69] −1.211 [−1.85, −.57]
tauSTPP 4.94 (0.93) 4.22 (1.16) 3.67 (1.36) -.668 [−1.01, −0.32] −1.141 [−1.77, −.51]
ES (between); d [95% CI] .47 [.04, .89] .14 [−.38, .65] .19 [−.54, .92]
BDIc mSTPP 18.05 (8.14) 10.65 (7.08) 7.41 (6.38) -.704 [−1.12, −.29] −0.985 [−1.62, −.35]
tauSTPP 18.50 (10.29) 13.44 (9.44) 11.81 (13.03) -.564 [−0.87, −.26] −0.605 [−1.04, −.17]
ES (between); d [95% CI] -.05 [−.47, .37] -.33 [−.84, .18] -.43 [−1.18, .32]
CGId mSTPP 5.22 (0.73) 3.87 (1.02) 3.21 (1.31) −1.908 [−2.57, −1.24] −2.937 [−4.20, −1.67]
tauSTPP 4.80 (0.78) 3.63 (1.31) 3.08 (1.44) −1.498 [−2.13, −.86] −2.193 [−3.29, −1.10]
ES (between); d [95% CI] .55 [.15, .95] .21 [−.32, .73] .10 [−.69, .89]
EQ-5De mSTPP 48.47 (32.81) 55.00 (36.36) 77.27 (15.42) .073 [−.33, .47] .782 [−.08, 1.64]
tauSTPP 59.68 (26.39) 61.90 (31.82) 49.14 (38.47) .142 [−.22, .51] -.719 [−1.34, −.10]
ES (between); d [95% CI] -.38 [−.77, .02] -.20 [−.67, .27] .90 [.20, 1.61]
A posteriori power for the difference after 25 sessions and baseline (α = 5% one-sided, two-sample t-test): a 17%, b 55% c 42% d 55% e 24%
Analysis Set = mITT Population (N = 105)
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remission rates after 12 months. However, baseline to 25
sessions effects for the improvement of social anxiety
(LSAS-OR, LSAS-SR and SPAI) were almost high ran-
ging between -.445 and −1.023) with an increase to
12 months follow-up (baseline to follow-up) for both
treatments. The large effects in secondary outcomes and
the corresponding low remission rates indicate a lower
variance of social anxiety in our study compared to the
study of Leichsenring et al. [9]. One reason for the lower
variance in this study may be due to the fact that the
participants in this study showed more severe presenta-
tions of SAD. Compared to the participants treated with
mSTPP in the study of Leichsenring et al. [9] partici-
pants in our study suffered from higher depression
scores (BDI), a 2-fold higher rate of personality disor-
ders and more comorbid mental disorders (for com-
parison see [32]). For such a highly distressed
population reaching the cut-off of 30 points on the
LSAS is much more difficult.
Another reason for the lower remission rates after 25
treatment sessions (resp. delayed increase in remission
rates during follow-up) might be associated with the
broader inclusion criteria (age up to 70 years, stable
medical treatments, e.g. SSRI without dose adaptation
were permitted) in our study, also leading to a more dif-
ficult to treat population.
Short-term (25 sessions) and long-term (12 months)
effects on depression (BDI) and especially clinical global
impression (CGI) are encouraging. Both conditions led
to further improvements following treatment termin-
ation. However, the manual mainly focused on symp-
toms of social anxiety disorder. There were no short
term improvements of quality of life (QoL) in both treat-
ments. The increase of QoL in the mSTPP and the de-
crease in the tauSTPP group is the only difference
between the settings and should therefore be interpreted
with caution because of the substantial data loss. Given
the slightly higher effect sizes for most of the outcome
criteria for mSTPP during treatment, it could be sur-
mised that improvement of QoL also took place earlier
compared to tauSTPP.
The strength of the study is its naturalistic character;
being much closer to real life conditions of therapists in
their private practice than under strongly controlled
RCTs. We would presume that this also led to the inclu-
sion of more severely impaired patients compared to the
main RCT. In order to ensure feasibility of the trial in
terms of dissemination and implementation, we pur-
posefully limited the effort for the participating therapist
(no training case, shorter training, fewer supervision)
compared to the main study. Thus, there are several lim-
itations. Firstly, due to the naturalistic character we also
did not do stringent adherence checks, which humbles
the internal validity of the study (differences between
the treatment arms are somewhat vague), but also in-
creases its generalizability describing more realistic con-
ditions of private practice. Secondly, only 49 therapists
participated in the study, which may cause a selection
bias by motivated therapist or those interested in re-
search activities. Thirdly, a relatively high drop-out rate
and the necessary change of the recruitment strategy due
to delay in recruitment might decrease the generalizability
of the results.
Despite its limitations this study is a promising at-
tempt to study the transfer of manualized treatments
into clinical practice.
We may conclude that the implementation of manua-
lized treatments pursued was not sufficient to reach
treatment effects of strictly controlled randomized con-
trolled trials. This raises the issue how dissemination
and implementation could be improved. Our strategy
was to keep demands on therapists low; we cannot be
sure if raising the demands of training for treatments for
specific disorders (as in our previous RCT) would really
be acceptable for the majority of therapists in private
practice. As alternatives, one might consider developing
transdiagnostic manuals suitable for a range of disorders
[34], devising more comprehensive self-learning mate-
rials (e.g. complementing written manuals by videotapes
of treatments) and—perhaps most importantly—introdu-
cing manualized treatments into psychodynamic training
and thereby a) increasing the openness of using specific
manuals, b) increasing the willingness to work in a
time-limited and focused treatment framework and c)
ensuring that the duration for training on manualized
approaches exceeds the 10 h of our study and there-
fore hopefully ensures a more competent delivery of
the treatment.
Our results might suggest that alternative treatment
strategies should be preferred for patients with a higher
symptom severity. One strategy could be a longer treat-
ment duration for a better outcome. It is an intriguing
question for future studies on the efficacy of PDT in so-
cial anxiety disorder, whether a symptom severity
adapted treatment duration increases treatment effects.
As recent guidelines [35] or meta-analyses (e.g. [36])
suggest, a combination of psychotherapy and medication
treatment may also be helpful for those patients with
anxiety disorders with worse outcome or higher initial
symptom severity.
Conclusions
The findings of our study indicate that the necessary
effort for the successful implementation of manua-
lized treatments is high. More comprehensive self-
learning materials and the introduction of manualized
treatments into psychodynamic training might be
promising attempts.
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Alternative treatment strategies should be preferred
for those patients with a higher initial symptom severity
and/or comorbid personality disorders. Possible treat-
ment strategies could be longer treatment duration or
combination of treatments (e.g. psychotherapy and
medication).
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